Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures (2021 - 2026)

Taysha Gene Therapies has disclosed Gains from Sales and Divestitures across 6 years of filings, most recently posting $1.8 million for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $1.8 million, up 69.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 69.42% YoY), and the FY2025 annual result was $1.2 million, up 285.79% from the prior year.
• Gains from Sales and Divestitures came in at $1.8 million for Q1 2026 at Taysha Gene Therapies, up from $1.2 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $1.8 million in Q1 2026 to a low of $17334.0 in Q1 2024.
• The 5-year median for Gains from Sales and Divestitures is $323031.0 (2024), against an average of $528040.6.
• Across the five-year window, Gains from Sales and Divestitures slumped 81.98% in 2023 and surged 5953.64% in 2025, its largest moves.
• Taysha Gene Therapies' Gains from Sales and Divestitures stood at $628921.0 in 2022, then dropped by 11.44% to $556989.0 in 2023, then plunged by 42.0% to $323031.0 in 2024, then soared by 285.79% to $1.2 million in 2025, then soared by 42.66% to $1.8 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at $1.8 million (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.